In all three EML4-ALK cell line models, significant tumor shrinkage was elicited by alectinib, but was followed by prompt tumor progression within three to four weeks of initiating treatment, despite continuous TKI therapy (Fig. 2b). Here, EML4 is linked to neoplasm.